ClinicalTrials.gg
CompletedNCT00195780Updated Jul 2, 2007

A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents

A Phase 3 interventional study of Divalproex Sodium (Depakote ER) in Bipolar I Disorder, sponsored by Abbott. Completed at 29 sites in United States. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2007-07-02.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
227
Allocation
Non-randomized
Ages
10 Years to 17 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate the long-term safety profile of the Investigational Medication Depakote ER in the treatment of Bipolar I Disorder, manic or mixed episode, in children and adolescents ages 10-17.

02

Conditions studied

  • Bipolar I Disorder

Keywords

  • Bipolar I Disorder
  • Depakote
03

In context

Lead sponsor

Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is between 10 and 17 years of age, inclusive, on Day 1 and weighs at least 60 lbs (27 kg).
  • Subject has a current psychiatric diagnosis of bipolar I disorder, manic or mixed episode, based on the K-SAD-PL interview and criteria.
  • Subject is an outpatient in a manic or mixed episode with a YMRS score of greater than or equal to 16 during Screening and at Day 1.

Exclusion criteria

Exclusion Criteria:

  • Has an Axis I disorder other than Attention Deficit Hyperactivity Disorder (ADHD), Obsessive Compulsive Disorder (OCD), Oppositional Defiant Disorder (ODD), Conduct Disorder (CD), Panic Disorder, Enuresis, Encopresis, Parasomnias, Agoraphobia, Specific Phobia, Social Phobia or Separation Anxiety Disorder; or subject has an Axis II disorder that would interfere with the subject's ability to comply with study procedures or confound interpretation of the study results. Subject meets criteria for substance abuse within the month prior to Screening, or meets the criteria for substance dependence within the three months prior to Screening, or exhibits signs of drug or alcohol intoxication or withdrawal at Day 1.
  • Is expected to require hospitalization for the current manic or mixed episode.
  • Is violent, homicidal, or suicidal such that, in the opinion of the investigator, the subject is at significant imminent risk of hurting self or others.
  • Has a history of a chronic or acute medical disorder that, in the opinion of the investigator, would preclude compliance with the protocol, or confound interpretation of the study results.
  • Has a history of, or is suspected of having a seizure disorder.
  • Has any central nervous system (CNS) neoplasm, CNS infection, demyelinating disease, degenerative neurological disease, or any progressive CNS disease.
  • Has count less than or equal to 100,000/µL
  • Has blood chemistry /AST value(s) greater than or equal to 2 times at screening.
  • Is taking a protocol allowed medication for ADHD that has not been stable for at least 3 months prior to Day 1, or that, in the investigator's opinion, may be exacerbating mood symptoms.
  • Requires anticoagulant drug therapy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
227 participants (actual)
06

What researchers measure

Primary outcomes

  1. Safety

Secondary outcomes

  1. Y-MRS

  2. CGI-S

  3. C-GAS

  4. CDRS-R

  5. CGSQ

  6. responders

  7. remitters

07

Study locations

29 sites
  • PCSD Feighner Research
    San Diego, California 92111, United States
  • PCSD Feighner Research
    San Marcos, California 92078, United States
  • Altamonte Springs, Florida 32701, United States
  • Segal Institute for Clinical Research
    Ft. Lauderdale, Florida 33319, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Segal Institute for Clinical Research
    North Miami, Florida 33161, United States
  • Kolin Research Group
    Winter Park, Florida 32789, United States
  • Northlake Medical Research Center
    Decatur, Georgia 30033, United States
  • Mountain West Clinical Trials
    Eagle, Idaho 83616, United States
  • Capstone Clinical Research
    Libertyville, Illinois 60048, United States
  • Clinco
    Terre Haute, Indiana 47802, United States
  • Cientifica Inc.
    Newton, Kansas 67114, United States
  • Psychiatric Associates
    Overland Park, Kansas 66211, United States
  • Brentwood Research Institute
    Shreveport, Louisiana 71101, United States
  • Acadia Hospital
    Bangor, Maine 04402-0422, United States
  • Pharmasite Research
    Baltimore, Maryland 21208, United States
  • North Carolina Neuropsychiatry, PA
    Chapel Hill, North Carolina 27514, United States
  • Odyssey Research
    Fargo, North Dakota 58104, United States
  • Neuro Behavioral Clinical Research, INC.
    Canton, Ohio 44708, United States
  • Psychiatric Professional Services
    Cincinnati, Ohio 45267-0559, United States
  • Rakesh Ranjan, M.D. & Associates, Inc.
    Lyndhurst, Ohio 44124, United States
  • IPS Research
    Oklahoma City, Oklahoma 73103, United States
  • Cutting Edge Research Group
    Oklahoma City, Oklahoma 73120, United States
  • Clinical Trials Specialists
    Bala Cynwyd, Pennsylvania 19004-1604, United States
  • UTHSC, Sept. of Psychiatry, College of Medicine
    Memphis, Tennessee 38105, United States
  • InSite Clinical Research
    DeSoto, Texas 75115, United States
  • Red Oak Psychiatry
    Houston, Texas 77090, United States
  • R/D Clinical Research
    Lake Jackson, Texas 77566, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98004, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 2, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00195780
Lead sponsor
Abbott
First posted
Sep 20, 2005
Start date
Feb 2005
Last update
Jul 2, 2007

Study contacts

Global Medical Information
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valproic Acid

Start the discussion